Advertisement

Cellular Oncology

, Volume 39, Issue 1, pp 89–95 | Cite as

Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis - A short Report

  • Yanjie You
  • Haijun Li
  • Xin Qin
  • Yonggang Ran
  • Fei WangEmail author
Report

Abstract

Background

Recently, we identified the esophageal carcinoma related gene 4 (ECRG4) as a novel candidate tumor suppressor gene and a promising therapeutic target in nasopharyngeal carcinoma (NPC). In addition, we found that reduced ECRG4 expression in NPC was associated with promoter hypermethylation. The aim of the current study was to assess the expression status of the ECRG4 protein in breast cancer and to clarify its clinicopathological significance and potential prognostic implications.

Methods

Western blotting was used to examine ECRG4 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, we performed ECRG4 immunohistochemistry on 113 clinicopathologically well-characterized breast cancer samples and assessed putative associations between its expression and overall patient survival rates.

Results

We found that ECRG4 protein expression was significantly reduced in the breast cancer tissues compared to the noncancerous tissues. Clinicopathological analyses revealed that loss of ECRG4 protein expression, observed in 41.6 % (47/113) of the primary breast cancer tissues tested, was significantly correlated with lymph node metastasis (P = 0.026), advanced tumor stage (P = 0.042) and unfavorable overall survival (P = 0.004). Additional multivariate analyses revealed that ECRG4 protein expression may serve as an independent prognostic factor for the prediction of patient survival (P = 0.033).

Conclusion

Our data suggest that loss of ECRG4 protein expression may be involved in tumor progression and may serve as a prognostic biomarker for breast cancer.

Keywords

ECRG4 Breast cancer Immunohistochemistry Prognosis 

Notes

Acknowledgments

This work was supported in part by the Science and Technology Planning Project of Henan Province, China (142102310464), the Key Research Foundation of Higher Education of Henan Province, China (15B320003), the Annual Natural Science Foundation of Luohe Medical College (2015-S-LMC02), the Natural Science Foundation of Hubei Province (2014CFC1154), the Foundation of Medical College of Hubei University of Arts and Science (YXKY 201402) and the Scientific Research Foundation for Doctoral Program of Hubei University of Arts and Science (X. Qin).

Compliance with ethical standards

Conflict of interest

No potential conflicts of interest were disclosed.

References

  1. 1.
    J. Russo, Y. F. Hu, X. Yang, I. H. Russo, Developmental, cellular, and molecular basis of human breast cancer. J. Natl. Cancer Inst. Monogr. 27, 17–37 (2000)CrossRefPubMedGoogle Scholar
  2. 2.
    C. M. Perou, T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lønning, A. L. Børresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747–752 (2000)CrossRefPubMedGoogle Scholar
  3. 3.
    J. Peppercorn, C. M. Perou, L. A. Carey, Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig. 26, 1–10 (2008)CrossRefGoogle Scholar
  4. 4.
    C. B. Moelans, E. J. Vlug, C. Ercan, P. Bult, H. Buerger, G. Cserni, P. J. van Diest, P. W. Derksen, Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cell. Oncol. 38, 397–405 (2015)CrossRefGoogle Scholar
  5. 5.
    D. E. Berardi, C. Flumian, P. B. Campodónico, A. J. Urtreger, M. I. Diaz Bessone, A. N. Motter, E. D. Bal de kier joffé, E. F. Farias, L. B. Todaro, Myoepithelial and Luminal breast Cancer Cells Exhibit Different Responses to all-Trans Retinoic Acid. Cell. Oncol. 38, 289–305 (2015)CrossRefGoogle Scholar
  6. 6.
    T. Yoda, K. M. McNamara, Y. Miki, Y. Onodera, K. Takagi, Y. Nakamura, T. Ishida, T. Suzuki, N. Ohuchi, H. Sasano, KLF15 in breast cancer: a novel tumor suppressor? Cell. Oncol. 38, 227–235 (2015)CrossRefGoogle Scholar
  7. 7.
    V. Papanikolaou, N. Stefanou, S. Dubos, I. Papathanasiou, M. Palianopoulou, V. Valiakou, A. Tsezou, Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes. Cell. Oncol. 38, 155–164 (2015)CrossRefGoogle Scholar
  8. 8.
    Y. You, W. Yang, X. Qin, F. Wang, H. Li, C. Lin, W. Li, C. Gu, Y. Zhang, Y. Ran, ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell. Oncol. 38, 205–214 (2015)CrossRefGoogle Scholar
  9. 9.
    L. W. Li, X. Y. Yu, Y. Yang, C. P. Zhang, L. P. Guo, S. H. Lu, Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int. J. Cancer 125, 1505–1513 (2009)CrossRefPubMedGoogle Scholar
  10. 10.
    R. Sabatier, P. Finetti, J. Adelaide, A. Guille, J. P. Borg, M. Chaffanet, L. Lane, D. Birnbaum, F. Bertucci, Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One 6, e27656 (2011)PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Y. Mori, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, H. Kurehara, R. Mori, K. Tomoda, R. Ogawa, T. Katada, K. Harata, Y. Fujii, Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol. Rep. 18, 981–985 (2007)PubMedGoogle Scholar
  12. 12.
    S. Götze, V. Feldhaus, T. Traska, M. Wolter, G. Reifenberger, A. Tannapfel, C. Kuhnen, D. Martin, O. Müller, S. Sievers, ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer 9, 447 (2009)PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    W. Li, X. Liu, B. Zhang, D. Qi, L. Zhang, Y. Jin, H. Yang, Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion. J. Exp. Clin. Cancer Res. 29, 89 (2010)PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martínez-Ruiz, V. Maldonado, NF-κB signaling in cancer stem cells: a promising therapeutic target? Cell. Oncol. 38, 327–339 (2015)CrossRefGoogle Scholar
  15. 15.
    T. Xu, D. Xiao, X. Zhang, ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo. Oncol. Lett. 5, 1921–1926 (2013)PubMedCentralPubMedGoogle Scholar
  16. 16.
    A. Kurabi, K. Pak, X. Dang, R. Coimbra, B. P. Eliceiri, A. F. Ryan, A. Baird, Ecrg4 attenuates the inflammatory proliferative response of mucosal epithelial cells to infection. PLoS One 8, e61394 (2013)PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    A. M. Gonzalez, S. Podvin, S. Y. Lin, M. C. Miller, H. Botfield, W. E. Leadbeater, A. Roberton, X. Dang, S. E. Knowling, E. Cardenas-Galindo, J. E. Donahue, E. G. Stopa, C. E. Johanson, R. Coimbra, B. P. Eliceiri, A. Baird, Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury. Fluids Barriers CNS. 8, 6 (2011)PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    J. Lee, X. Dang, A. Borboa, R. Coimbra, A. Baird, B. P. Eliceiri, Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro-Oncology 17, 685–696 (2015)CrossRefPubMedGoogle Scholar
  19. 19.
    S. Kao, A. Shaterian, D. M. Cauvi, X. Dang, H. B. Chun, A. De Maio, T. W. Costantini, R. Coimbra, B. P. Eliceiri, A. Baird, Pulmonary preconditioning, injury, and inflammation modulate expression of the candidate tumor suppressor gene ECRG4 in lung. Exp. Lung Res. 41, 162–172 (2015)CrossRefPubMedGoogle Scholar
  20. 20.
    S. Podvin, X. Dang, M. Meads, A. Kurabi, T. Costantini, B. P. Eliceiri, A. Baird, R. Coimbra, Esophageal cancer-related gene-4 (ECRG4) interactions with the innate immunity receptor complex. Inflamm. Res. 64, 107–118 (2015)CrossRefPubMedGoogle Scholar
  21. 21.
    J. Chen, C. Liu, L. Yin, W. Zhang, The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism. Tumour Biol. 36, 1081–1089 (2015)CrossRefPubMedGoogle Scholar
  22. 22.
    C. P. Jiang, B. H. Wu, B. Q. Wang, M. Y. Fu, M. Yang, Y. Zhou, F. Liu, Overexpression of ECRG4 enhances chemosensitivity to 5-fluorouracil in the human gastric cancer SGC-7901 cell line. Tumour Biol. 34, 2269–2273 (2013)CrossRefPubMedGoogle Scholar
  23. 23.
    J. Lu, M. Wen, Y. Huang, X. He, Y. Wang, Q. Wu, Z. Li, A. Castellanos-Martin, M. Abad, J. J. Cruz-Hernandez, C. A. Rodriguez, J. Pérez-Losada, J. H. Mao, G. Wei, C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics. 8, 571–583 (2013)PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    B. Gyorffy, P. Surowiak, J. Budczies, A. Lanczky, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8, e82241 (2013)PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    M. W. Beckmann, J. U. Blohmer, S. D. Costa, T. Decker, I. Diel, T. Dimpfl, W. Eiermann, T. Fehm, K. Friese, F. Jänicke, W. Janni, W. Jonat, M. Kiechle, U. Köhler, H. J. Lück, N. Maass, K. Possinger, A. Rody, A. Scharl, A. Schneeweiss, C. Thomssen, D. Wallwiener, A. Welt, 13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancerevidence, controversies, consensus - opinion of a German team of experts (Zurich 2013). Breast Care (Basel). 8, 221–229 (2013)Google Scholar
  26. 26.
    A. Baird, J. Lee, S. Podvin, A. Kurabi, X. Dang, R. Coimbra, T. Costantini, V. Bansal, B. P. Eliceiri, Esophageal cancer-related gene 4 at the interface of injury, inflammation, infection, and malignancy. Gastric Cancer 2014, 131–142 (2014)Google Scholar
  27. 27.
    E. Steck, S. Breit, S. J. Breusch, M. Axt, W. Richter, Enhanced expression of the human chitinase 3-like 2 gene (YKL-39) but not chitinase 3-like 1 gene (YKL-40) in osteoarthritic cartilage. Biochem. Biophys. Res. Commun. 299, 109–115 (2002)CrossRefPubMedGoogle Scholar
  28. 28.
    O. Mirabeau, E. Perlas, C. Severini, E. Audero, O. Gascuel, R. Possenti, E. Birney, N. Rosenthal, C. Gross, Identification of novel peptide hormones in the human proteome by hidden markov model screening. Genome Res. 17, 320–327 (2007)PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Y. B. Wang, C. F. Ba, Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance. Hepato-Gastroenterology 59, 1696–1698 (2012)PubMedGoogle Scholar
  30. 30.
    D. K. Vanaja, M. Ehrich, D. Van den Boom, J. C. Cheville, R. J. Karnes, D. J. Tindall, C. R. Cantor, C. Y. Young, Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Investig. 27, 549–560 (2009)CrossRefGoogle Scholar
  31. 31.
    J. Matsuzaki, T. Torigoe, Y. Hirohashi, Y. Tamura, H. Asanuma, E. Nakazawa, E. Saka, K. Yasuda, S. Takahashi, N. Sato, Expression of ECRG4 is associated with lower proliferative potential of esophageal cancer cells. Pathol. Int. 63, 391–397 (2013)CrossRefPubMedGoogle Scholar
  32. 32.
    Y. Mori, H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitsui, H. Kurehara, R. Mori, K. Tomoda, R. Ogawa, T. Katada, K. Harata, Y. Fujii, Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol. Rep. 18, 981–985 (2007)PubMedGoogle Scholar
  33. 33.
    A. Shaterian, S. Kao, L. Chen, L. A. DiPietro, R. Coimbra, B. P. Eliceiri, A. Baird, The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Arch. Dermatol. Res. 305, 141–149 (2013)PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    S. J. Payne, R. L. Bowen, J. L. Jones, C. A. Wells, Predictive markers in breast cancer–the present. Histopathology 52, 82–90 (2008)CrossRefPubMedGoogle Scholar
  35. 35.
    C. A. Castaneda, E. Andrés, C. Barcena, H. L. Gómez, H. Cortés-Funés, E. Ciruelos, Behaviour of breast cancer molecular subtypes through tumour progression. Clin. Transl. Oncol. 14, 481–485 (2012)CrossRefPubMedGoogle Scholar

Copyright information

© International Society for Cellular Oncology 2015

Authors and Affiliations

  • Yanjie You
    • 1
    • 2
    • 3
  • Haijun Li
    • 5
  • Xin Qin
    • 6
  • Yonggang Ran
    • 7
  • Fei Wang
    • 3
    • 4
    Email author
  1. 1.Pathological Examination and Research CenterLuohe Medical CollegeLuoheChina
  2. 2.Department of PharmacyLuohe Medical CollegeLuoheChina
  3. 3.Luohe Key Laboratory of Medical BioengineeringLuohe Medical CollegeLuoheChina
  4. 4.Bioengineering LaboratoryLuohe Medical CollegeLuoheChina
  5. 5.Department of Radiation OncologyThe Second People’s Hospital of Neijiang CityNeijiangChina
  6. 6.Medical CollegeHubei University of Arts and ScienceXiangyangChina
  7. 7.Department of Teaching and TrainingBethune Military Medical NCO Academy of PLAShijiazhuangChina

Personalised recommendations